SCHEMBL2652665

SCHEMBL2652665

N#Cc1cc(Cl)ccc1-c1cc(N)ccc1F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.44
MEN1 O00255 2/20 0.44
MAPT P10636 2/20 0.44
HPGD P15428 2/20 0.44
KMT2A Q03164 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C19 P33261 1/20 0.44
KHK P50053 1/20 0.39
ALDH1A1 P00352 3/20 0.37
USP2 O75604 1/20 0.37
BRD4 O60885 1/20 0.35
CNR1 P21554 3/20 0.35
CNR2 P34972 3/20 0.35
LMNA P02545 1/20 0.35
CYP2A6 P11509 1/20 0.35
VCAM1 P19320 1/20 0.35
NOS2 P35228 1/20 0.35
CYP11B1 P15538 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2650000 0.85 GABRA1 (0.42) KDM4EMEN1MAPTHPGDKMT2A
SCHEMBL2653493 0.81 BIRC5 (0.36) KMT2AALDH1A1CNR1CNR2LMNA
SCHEMBL2651126 0.80 ALOX5AP (0.44) KDM4EMEN1MAPTHPGDKMT2A
SCHEMBL2638947 0.76 KDM4E (0.55) KDM4EMEN1MAPTHPGDKMT2A
SCHEMBL21020966 0.76 CYP3A4 (0.37) KDM4EMEN1MAPTHPGDKMT2A
SCHEMBL2648034 0.75 GABRA1 (0.42) KDM4EMEN1MAPTHPGDKMT2A
SCHEMBL2652114 0.75 GABRA1 (0.44) KDM4EHPGDKHKALDH1A1USP2
SCHEMBL2650963 0.75 VCAM1 (0.54) KDM4EMEN1MAPTKMT2ACYP3A4
SCHEMBL22115306 0.75 CYP11B2 (0.43) KDM4EALDH1A1CNR1CNR2CYP11B1
SCHEMBL481131 0.74 CYP2A6 (0.46) KHKCYP2A6VCAM1NOS2CYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1381606-B1 IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME (GB) 2005-07-20 EP disclosed
US-6900215-B2 For therapy of disorders of central nervous system, including anxiety, convulsions and cognitive disorders MERCK SHARP & DOHME LTD. (GB) 2005-05-31 US disclosed
EP-1381606-A1 IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LTD. (GB) 2004-01-21 EP disclosed
US-20020193385-A1 Imidazo-pyrimidine derivatives as ligands for gaba receptors MERCK SHARP & DOHME (UK) LIMITED (GB) 2002-12-19 US disclosed
WO-2002074773-A1 IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LIMITED (GB) 2002-09-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193385-A1 Imidazo-pyrimidine derivatives as ligands for gaba receptors GABRA3, GABRA1, GABRA2 KDM4E 3725/4885MEN1 4742/4885MAPT 754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.